Phraxis Inc. has achieved a major milestone with FDA approval of its EndoForce™ Connector, a breakthrough endovascular device designed to modernize arteriovenous graft (AVG) creation for dialysis patients. Unlike traditional surgical methods that require venous dissection, EndoForce™ enables a minimally invasive endovascular venous anastomosis, simplifying the procedure while preserving tissue integrity. This patented innovation offers coaxial alignment between the graft and vein, improving procedural precision and potentially reducing complications that commonly affect long-term dialysis access.

The device incorporates several proprietary features including anchoring barbs for secure placement, a nitinol segment covered in ePTFE for optimal vessel and graft conformity, and a compressible region that expands to ensure stability within the AVG. This design promotes laminar blood flow, minimizing turbulent shear stress—one of the main contributors to endothelial buildup and graft failure. In a pivotal multicenter clinical trial, EndoForce™ achieved a 92% six-month patency rate, meeting primary efficacy endpoints and demonstrating strong procedural success and reliability across patient cases.